Literature DB >> 18713659

Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations.

Domenico Girelli1, Ivana De Domenico, Claudia Bozzini, Natascia Campostrini, Fabiana Busti, Annalisa Castagna, Nadia Soriani, Laura Cremonesi, Maurizio Ferrari, Romano Colombari, Diane McVey Ward, Jerry Kaplan, Roberto Corrocher.   

Abstract

BACKGROUND/AIMS: Clinico-pathological manifestations of ferroportin (Fpn) disease (FD) are heterogeneous, with some patients presenting with iron overload predominantly in macrophages ("M" phenotype), others predominantly in hepatocytes ("H" phenotype). This appears to reflect functional heterogeneity of Fpn mutants, with loss-of-function generally resulting in the M type.
METHODS: Two unrelated probands with "non-HFE" hemochromatosis were screened for Fpn mutations. Mutants were functionally characterized by immunofluorescence microscopy, evaluation of their ability to bind hepcidin and export iron, and by expressing them in zebrafish.
RESULTS: Two novel Fpn mutations were identified: I152F in patient-1, presenting with typical M phenotype; and L233P in patient-2, presenting with ambiguous features (massive overload in both macrophages and hepatocytes). Molecular studies suggested loss of function in both cases. The I152F, normally localized on cell membrane and internalized by hepcidin, showed a unique "primary" deficit of iron export capability. The L233P did not appropriately traffic to cell surface. Loss of function was confirmed by expressing both mutants in vivo in zebrafish, resulting in iron limited erythropoiesis. Clinical manifestations were likely enhanced in both patients by non-genetic factors (HCV, alcohol).
CONCLUSIONS: The combination of careful review of clinico-pathological data with molecular studies can yield compelling explanations for phenotype heterogeneity in FD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713659      PMCID: PMC2605969          DOI: 10.1016/j.jhep.2008.05.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  30 in total

Review 1.  Iron overload due to mutations in ferroportin.

Authors:  Ivana De Domenico; Diane McVey Ward; Giovanni Musci; Jerry Kaplan
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

2.  Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.

Authors:  Hal Drakesmith; Lisa M Schimanski; Emma Ormerod; Alison T Merryweather-Clarke; Vip Viprakasit; Jon P Edwards; Emma Sweetland; Judy M Bastin; Diana Cowley; Yingyong Chinthammitr; Kathryn J H Robson; Alain R M Townsend
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

3.  The molecular basis of ferroportin-linked hemochromatosis.

Authors:  Ivana De Domenico; Diane McVey Ward; Elizabeta Nemeth; Michael B Vaughn; Giovanni Musci; Tomas Ganz; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-13       Impact factor: 11.205

4.  Functional consequences of ferroportin 1 mutations.

Authors:  Xiao-Bing Liu; Funmei Yang; David J Haile
Journal:  Blood Cells Mol Dis       Date:  2005 Jul-Aug       Impact factor: 3.039

5.  Genetic and clinical heterogeneity of ferroportin disease.

Authors:  L Cremonesi; Laura Cemonesi; Gian Luca Forni; Nadia Soriani; Martina Lamagna; Isabella Fermo; Filomena Daraio; Anna Galli; Daniela Pietra; Luca Malcovati; Maurizio Ferrari; Clara Camaschella; Mario Cazzola
Journal:  Br J Haematol       Date:  2005-12       Impact factor: 6.998

6.  Hepcidin in iron overload disorders.

Authors:  George Papanikolaou; Michalis Tzilianos; John I Christakis; Dionisios Bogdanos; Konstantina Tsimirika; Julie MacFarlane; Y Paul Goldberg; Nikos Sakellaropoulos; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

7.  Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.

Authors:  Elizabeta Nemeth; Marie S Tuttle; Julie Powelson; Michael B Vaughn; Adriana Donovan; Diane McVey Ward; Tomas Ganz; Jerry Kaplan
Journal:  Science       Date:  2004-10-28       Impact factor: 47.728

8.  In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.

Authors:  Lisa M Schimanski; Hal Drakesmith; Alison T Merryweather-Clarke; Vip Viprakasit; Jon P Edwards; Emma Sweetland; Judy M Bastin; Diana Cowley; Yingyong Chinthammitr; Kathryn J H Robson; Alain R M Townsend
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

Review 9.  Balancing acts: molecular control of mammalian iron metabolism.

Authors:  Matthias W Hentze; Martina U Muckenthaler; Nancy C Andrews
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

10.  Excess iron into hepatocytes is required for activation of collagen type I gene during experimental siderosis.

Authors:  R Gualdi; G Casalgrandi; G Montosi; E Ventura; A Pietrangelo
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  13 in total

Review 1.  Zebrafish models of human liver development and disease.

Authors:  Benjamin J Wilkins; Michael Pack
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

2.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

3.  Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing.

Authors:  Ludovica Ferbo; Paola M Manzini; Sadaf Badar; Natascia Campostrini; Alberto Ferrarini; Massimo Delledonne; Tiziana Francisci; Valter Tassi; Adriano Valfrè; Anna M Dall'omo; Sergio D'antico; Domenico Girelli; Antonella Roetto; Marco De Gobbi
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

4.  The three isoforms of hepcidin in human serum and their processing determined by liquid chromatography-tandem mass spectrometry (LC-tandem MS).

Authors:  Lynda Addo; Katsuya Ikuta; Hiroki Tanaka; Yasumichi Toki; Mayumi Hatayama; Masayo Yamamoto; Satoshi Ito; Motohiro Shindo; Yusuke Sasaki; Yasushi Shimonaka; Mikihiro Fujiya; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2016-01       Impact factor: 2.490

5.  Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin.

Authors:  Sergei Nekhai; Min Xu; Altreisha Foster; Ishmael Kasvosve; Sharmin Diaz; Roberto F Machado; Oswaldo L Castro; Gregory J Kato; James G Taylor; Victor R Gordeuk
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

6.  Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS.

Authors:  Natascia Campostrini; Annalisa Castagna; Federica Zaninotto; Valeria Bedogna; Nicola Tessitore; Albino Poli; Nicola Martinelli; Antonio Lupo; Oliviero Olivieri; Domenico Girelli
Journal:  J Biomed Biotechnol       Date:  2010-04-15

7.  Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo.

Authors:  Shan Soe-Lin; Sameer S Apte; Billy Andriopoulos; Marc C Andrews; Matthias Schranzhofer; Tanya Kahawita; Daniel Garcia-Santos; Prem Ponka
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

8.  Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.

Authors:  Roman Mayr; Andreas R Janecke; Melanie Schranz; William J H Griffiths; Wolfgang Vogel; Antonello Pietrangelo; Heinz Zoller
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

9.  Host iron withholding demands siderophore utilization for Candida glabrata to survive macrophage killing.

Authors:  Tracy Nevitt; Dennis J Thiele
Journal:  PLoS Pathog       Date:  2011-03-17       Impact factor: 6.823

Review 10.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.